Functional knockout of FUT8 in Chinese hamster ovary cells using CRISPR/Cas9 to produce a defucosylated antibody

Engineering in Life Sciences

Volumn 15, Issue 6, 2015, Pages 660-666

  Sun, Tao ^a,b   Li, Chaodong ^a,b   Han, Lei ^a,b   Jiang, Hua ^c   Xie, Yueqing ^c   Zhang, Baohong ^a,b   Qian, Xiuping ^a,b   Lu, Huili ^a,b   Zhu, Jianwei ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Jecho Laboratories Inc   (United States)

Author keywords

Antibody; Antibody dependent cellular cytotoxicity; CHO K1 cells; CRISPR Cas9; Fucose

Indexed keywords

AMINO ACIDS; CELL CULTURE; CELLS; CLONE CELLS; CLONING; CYTOLOGY; CYTOTOXICITY; GENE ENCODING; GENES; PROTEINS;

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITIES; BIOLOGICAL THERAPEUTICS; CHINESE HAMSTER OVARY CELLS; CRISPR/CAS9; FUCOSE; HOMOLOGOUS RECOMBINATION; THERAPEUTIC ANTIBODIES; ZINC FINGER NUCLEASE;

ANTIBODIES;

AGGLUTININ; ASPARAGINE; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; FUCOSE; FUCOSYLTRANSFERASE; FUCOSYLTRANSFERASE 8; GLYCAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE;

ANTIBODY; CELLS AND CELL COMPONENTS; CLONE; EGG; ENZYME ACTIVITY; MOLECULAR ANALYSIS; PROTEIN; RODENT; ZINC;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL VIABILITY; CHO CELL LINE; CLONE; FUCOSYLATION; HOMOLOGOUS RECOMBINATION; INDEL MUTATION; LENTIL; NONHUMAN; TECHNOLOGY;

CRICETULUS GRISEUS; LENS CULINARIS;

EID: 84941187809     PISSN: 16180240     EISSN: 16182863     Source Type: Journal    
DOI: 10.1002/elsc.201400218     Document Type: Article

References (36)

1. Deb, R., Chakraborty, S., Veeregowda, B., Verma, A. K. et al., Monoclonal antibody and its use in the diagnosis of livestock diseases. Adv. Biosci. Biotechnol. 2013, 4, 50-62.
2. Elvin, J. G., Couston, R. G., vander Walle, C. F., Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int. J. Pharmaceutics 2013, 440, 83-98.
3. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P. et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002, 99, 754-758.
4. Clynes, R. A., Towers, T. L., Presta, L. G., Ravetch, J. V., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6, 443-446.
5. Rademacher, T., Homans, S., Parekh, R., Dwek, R., Immunoglobulin G as a glycoprotein. Biochem. Soc. Symp. 1985, 51, 131-148.
6. Peipp, M., vanBueren, J. J. L., Schneider-Merck, T., Bleeker, W. W. et al., Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008, 112, 2390-2399.
7. Zhu, J., Mammalian cell protein expression for biopharmaceutical production. Biotechnol. Adv. 2012, 30, 1158-1170.
8. Kanda, Y., Yamane-Ohnuki, N., Sakai, N., Yamano, K. et al., Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 2006, 94, 680-688.
9. Becker, D. J., Lowe, J. B., Fucose: Biosynthesis and biological function in mammals. Glycobiology 2003, 13, 41R-53R.
10. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E. et al., The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278, 3466-3473.
11. Malphettes, L., Freyvert, Y., Chang, J., Liu, P. Q. et al., Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol. Bioeng. 2010, 106, 774-783.
12. Zwaka, T. P., Thomson, J. A., Homologous recombination in human embryonic stem cells. Nat. Biotechnol. 2003, 21, 319-321.
13. Yamane-Ohnuki, N., Kinoshita, S., Inoue-Urakubo, M., Kusunoki, M. et al., Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 2004, 87, 614-622.
14. Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N. et al., A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011, 39, 9283-9293.
15. Walsh, R. M., Hochedlinger, K., A variant CRISPR-Cas9 system adds versatility to genome engineering. Proc. Natl. Acad. Sci. 2013, 110, 15514-15515.
16. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. et al., Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11, 636-646.
17. Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y. et al., Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 2008, 26, 808-816.
18. Barrangou, R., Fremaux, C., Deveau, H., Richards, M. et al., CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315, 1709-1712.
19. Cong, L., Ran, F. A., Cox, D., Lin, S. et al., Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819-823.
20. Ronda, C., Pedersen, L. E., Hansen, H. G., Kallehauge, T. B. et al., Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. Biotechnol. Bioeng. 2014, 111, 1604-1616.
21. Mali, P., Yang, L., Esvelt, K. M., Aach, J. et al., RNA-guided human genome engineering via Cas9. Science 2013, 339, 823-826.
22. Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V. et al., Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013, 8, 2281-2308.
23. Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L. et al., Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 2013, 31, 227-229.
24. Lim, S. H., Beers, S. A., French, R. R., Johnson, P. W. et al., Anti-CD20 monoclonal antibodies: Historical and future perspectives. Haematologica 2010, 95, 135-143.
25. Hober, S., Nord, K., Linhult, M., Protein A chromatography for antibody purification. J. Chromatogr. B 2007, 848, 40-47.
26. Miyoshi, E., Moriwaki, K., Terao, N., Tan, C.-C. et al., Fucosylation is a promising target for cancer diagnosis and therapy. Biomolecules 2012, 2, 34-45.
27. Wang, X., Gu, J., Ihara, H., Miyoshi, E. et al., Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J. Biol. Chem. 2006, 281, 2572-2577.
28. Hsu, P. D., Lander, E. S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157, 1262-1278.
29. Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L. et al., High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 2013, 31, 822-826.
30. Ran, F., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S. et al., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154, 1380-1389.
31. Lübke, T., Marquardt, T., Etzioni, A., Hartmann, E. et al., Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat. Genet. 2001, 28, 73-76.
32. Rajendra, Y., Kiseljak, D., Baldi, L., Hacker, D. L. et al., A simple high-yielding process for transient gene expression in CHO cells. J. Biotechnol. 2011, 153, 22-26.
33. Coulier, L., Zha, Y., Bas, R., Punt, P. J., Analysis of oligosaccharides in lignocellulosic biomass hydrolysates by high-performance anion-exchange chromatography coupled with mass spectrometry (HPAEC-MS). Bioresour. Technol. 2013, 133, 221-231.
34. Qiu, Y., Patwa, T. H., Xu, L., Shedden, K. et al., Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 2008, 7, 1693-1703.
35. Tsai, S. Q., Wyvekens, N., Khayter, C., Foden, J. A. et al., Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 2014, 32, 569-576.
36. Zhu, J., Mammalian cell protein expression for biopharmaceutical production. Biotechnol. Adv. 2012, 30, 1158-1170.